As part of the David Geffen School of Medicine at UCLA's Unified Research Themes, the UCLA Cancer Research Theme was created to catalyze partnerships between UCLA’s top scientists and clinicians. Within that initiative, the UCLA Jonsson Comprehensive Cancer (JCCC) is a world-renowned leader in cancer research, with a prodigious 20-year history of successfully translating discoveries made in the lab into new cancer treatments. The cancer center maintains the highest degree of excellence in its mission to develop new approaches to cancer detection, prevention and treatment, and to deliver the latest medical advances to patients and their families. As part of the UCLA Cancer Research Theme, its institutional commitment is to foster cross-departmental collaboration, guide the next generation of medical researchers, and lead community and educational efforts with a focus on underserved populations.
Many UCLA scientists and physicians have made important contributions to understanding cancer - With a membership of more than 500 physicians and scientists, UCLA's Jonsson Comprehensive Cancer Center is one of the largest comprehensive cancer centers in the nation. Its members handle more than 20,000 patient visits per year and conduct hundreds of clinical trials, and numerous FDA-approved therapies were developed based on the basic science and clinical research done by the JCCC’s award-winning scientists.
Director of clinical and translational research at the Jonsson Cancer Center, Dr. Slamon and his colleagues conducted the laboratory and clinical research that led to the development of Herceptin, the first targeted cancer therapy approved by the FDA.
A pioneer in the assessment of quality of life in breast cancer patients and survivors, Dr. Ganz is director of prevention and control research at the Jonsson Cancer Center, and has spent the past 20 years conducting systematic research on the health-related quality of life impact of cancer and its treatment.
Dr. Ribas is an internationally recognized leader in the using immune checkpoint inhibitors to treat melanoma, and was principal investigator on the trial that tested the breakthrough immunotherapy drug pembrolizumab (commercialized as Keytruda).
Director of the UCLA brain SPORE, Dr. Liau and her colleagues are conducting pioneering research in the use of dendritic cells to activate T cells to treat brain cancer.
UCLA researchers are world-renowned for their pioneering discoveries in cancer research, prevention and treatment.
Learn More →
After her second diagnosis with cancer, cinematographer and filmmaker Lila Javan had to put her dream of climbing Mt. Kilimanjaro on hold.
Watch her story →